风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 9月17日，港股通医疗ETF富国（159506）跌0.67%，成交额4.63亿元。当日份额增加1400.00万份，最新 份额为22.26亿份，近20个交易日份额增加1.57亿份。最新资产净值计算值为36.58亿元。 港股通医疗ETF富国（159506）业绩比较基准为恒生港股通医疗保健指数收益率(使用估值汇率折算)， 管理人为富国基金管理有限公司，基金经理为田希蒙，成立（2023-06-14）以来回报为64.37%，近一个 月回报为0.23%。 来源：新浪基金∞工作室 ...

9月首个交易日，港股医疗领涨市场，午后创新药、疫苗等细分领域情绪火热，表现亮眼。截至发稿， 创新药ETF富国（159748）盘中涨幅达4.43%，成分股长春高新、华海药业、健康元均涨停。此外，港 股通医疗ETF富国（159506）盘中涨幅达3.85%。 消息面上，8月28日，国家医保局正式公布通过2025年医保及商保创新药目录调整初步形式审查药品名 单。两份目录均以新药为主，"百万抗癌药"CAR-T产品、多个"全球首个且唯一"的产品出现在目录当 中。 机构表示，医药生物行业2025H1呈现边际改善趋势，制药及CXO板块复苏明显，2025H1收入、归母净 利润增速分别为6.9%、56.1%，毛利率提升至77.7%，销售和研发费用率持续下降。目前我国创新药进 入成果兑现阶段，研发进展催化较多，望持续作为2025年医药板块投资主线。 ...

今日港股医疗板块高开高走，延续近日景气行情，创新药、疫苗等细分领域表现亮眼，截至发稿，港股 通医疗ETF富国（159506）盘中涨幅达3.34%，其成分股绿叶制药、药明康德涨超8%，先声药业涨超 7%。此外，创新药ETF富国（159748）盘中涨幅达3.55%，成分股药明康德涨超8%，泰格医药、石药 集团涨超7%。 港股通医疗ETF富国（159506）紧密跟踪恒生港股通医疗保健指数（HSSCHI），根据指数编制方案， 成分股中最近两年平均研究开发/收入排名位列最低的公司会被剔除，研发支出占比及创新药业务占比 较高，创新属性突出，帮助投资者精准捕捉港股医药板块投资机会。 创新药ETF富国（159748）紧密跟踪SHS创新药（CSI：931409）指数，指数从市场中选取主营创新药 物研发、生产和销售的上市公司证券作为指数样本，聚焦医药生物行业中创新型制药企业，以反映创新 药领域内优质上市公司证券的整体表现，帮助投资者精准捕捉医药板块创新药领域投资机会。 消息面上，近期国家医保局召开座谈会，明确表示将通过医保价格政策赋能药械创新，包括统一新设医 疗服务价格项目、推动高水平科技创新成果加快进入临床应用、研究实行新上市 ...

Group 1 - The Hong Kong stock market's healthcare sector showed strong performance, with significant gains in innovative drugs, biopharmaceuticals, medical devices, and medical services [1] - The Hong Kong Stock Connect Medical ETF (159506) saw an intraday increase of 3.83%, with constituent stocks like Lepu Biopharma-B, Kangfang Biopharma, and Kintor Pharmaceuticals rising over 9% [1] - Recent announcements of mergers and new drug trials by leading companies have positively influenced market sentiment, with institutions noting that acquisitions will enhance core competitiveness in relevant fields [1] Group 2 - The innovative drug ETF (S159748) recorded an intraday rise of 2.96%, reflecting growing investor interest in the sector [1] - The domestic innovative drug industry is evolving with new transaction models like NewCo, particularly in the ADC sector, which has the highest trading interest, along with opportunities in dual antibodies/multi-antibodies and cutting-edge technologies like small nucleic acids/mRNA [1] - The current landscape shows a rich reserve of domestic innovative drug assets with significant trading value, alongside multinational pharmaceutical companies facing patent cliffs, indicating sustained enthusiasm for domestic innovative drug transactions abroad [1] Group 3 - The Hong Kong Stock Connect Medical ETF (159506) closely tracks the Hang Seng Stock Connect Healthcare Index (HSSCHI), with a unique index compilation scheme that excludes companies with the lowest average R&D/income rankings over the past two years [1] - Companies with high R&D expenditure ratios and a significant share of innovative drug business are prioritized, aiding investors in accurately capturing investment opportunities in the Hong Kong pharmaceutical sector [1]